Clinical trials: Parathyroid Disease
Adynamic Bone Disease, Chronic Kidney Diseases
Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The purpose of the study is to assess the safety and efficacy of recombinant human parathyroid hormone for…
- Conditions
- Adynamic Bone Disease, Chronic Kidney Diseases, Cardiac Disease, Chronic Kidney Disease-Mineral and Bone Disorder
- Trial name
- NCT04522622
- Testing
- Teriparatide, DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT, Bone biopsy
- Where
- 4 sites in Denmark
- Volunteers
- 48 people
- Sponsor
- Ditte Hansen
Osteopenia, Osteoporosis
Once Weekly Parathyroid Hormone for Osteoporosis
Daily parathyroid hormone (PTH) is approved by the FDA for the treatment of osteoporosis. This study will evaluate the safety and effectiveness of PTH when given once a week.
- Trial name
- NCT00065637
- Testing
- Teriparatide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Nephrology
A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)
Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters
- Trial name
- NCT00189501
- Testing
- Sensipar®
- Volunteers
- 1,000 people
- Sponsor
- Amgen
Head and Neck Neoplasms
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell…
- Trial name
- NCT01087970
- Testing
- Pemetrexed, Cetuximab, Carboplatin
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company
Hyperparathyroidism, Primary
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
This multicenter, open-label, single-arm, extension study was designed to evaluate long-term tolerability, safety, and efficacy of cinacalcet. Subjects were enrolled immediately after they completed the parent study, 990120.
- Trial name
- NCT00936988
- Testing
- cinacalcet
- Volunteers
- 45 people
- Sponsor
- Amgen
Endstage Renal Disease
The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis
The purpose of this trial is to examine the effect of increasing dialyse magnesium on serum calcification propensity in subjects with end-stage renal disease treated with haemodialysis.
- Trial name
- NCT02977117
- Testing
- Dialysate magnesium (1.0 mmol/L), Dialysate magnesium (0.5 mmol/L)
- Where
- Denmark
- Volunteers
- 59 people
- Sponsor
- Iain Bressendorff